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Objectives. We sought to determine the precise myocardial
effects of OPC-18790 as demonstrated by intracoronary adminis-
tration.
Background. Although previous studies have determined the
cardiovascular effects of a novel intravenous inotrope, OPC-
18790, the observed benefits on contractile and diastolic function
may have been confounded by the marked changes in peripheral
loading associated with this drug when given intravenously.
Methods. Eight heart failure patients received intracoronary
OPC-18790 at 31.25 mg/min for 20 min, and then at 62.5 mg/min
for another 20 min. Hemodynamic variables and pressure–volume
indexes using the conductance catheter method were determined
at baseline and then after the two doses.
Results. There were no significant effects on heart rate, cardiac
output or loading conditions, including afterload as determined
by systemic vascular resistance and arterial elastance (Ea) and
preload as determined by end-diastolic volume (EDV). There were
significant increases in end-systolic elastance (Ees) from 0.74 6
0.11 to 0.90 6 0.16 mm Hg/ml at 31.25 mg/min and to 1.37 6
0.33 mm Hg/ml at 62.5 mg/min (p < 0.05 by analysis of variance
[ANOVA]). Diastolic function improved, as determined by the
time constant for isovolumetric relaxation tau, which decreased
significantly from baseline to 31.25 mg/min (94 6 9 to 79 6 9 ms,
p < 0.05), and did not shorten further at 62.5 mg/min (78 6 8 ms,
p 5 NS). There were significant decreases in right atrial pressure
(9 6 1 to 7 6 1 mm Hg, p < 0.01 by ANOVA) and mean pulmonary
artery wedge pressure (21 6 3 to 16 6 2 mm Hg, p < 0.05 by
ANOVA). This fall in filling pressures was not accompanied by
any change in EDV. Inspection of the diastolic portion of the
pressure–volume curve confirmed a downward shift consistent
with pericardial release in five of the eight patients.
Conclusions. Intracoronary administration of OPC-18790 dem-
onstrates that the direct myocardial effects of this agent include a
modest increase in inotropy and improvement in diastolic func-
tion, both of which occur without increases in heart rate, indicat-
ing that this agent may be beneficial for the intravenous treatment
of congestive heart failure.
(J Am Coll Cardiol 1998;31:1344–51)
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OPC-18790 has been shown to increase contractility (1), which
is thought to be mediated in part by phosphodiesterase inhi-
bition (2). However, unlike other phosphodiesterase inhibitors,
these effects occur without any change in heart rate (1,3),
which is thought to be the consequence of inhibition of inward
potassium and delayed rectifier currents (4). We previously
studied the effects of intravenous OPC-18790 on pressure–
volume relations in human heart failure, demonstrating that
OPC-18790 increased end-systolic elastance (Ees), a relatively
load-independent measure of contractility, by up to 172%, and
decreased the time constant for isovolumetric relaxation tau by
20% (1). These effects were also accompanied by a 30% fall in
atrial and pulmonary artery pressures and a 40% reduction in
afterload. As a result, OPC-18790 has been classified as a
positive inotrope with potent venous and arterial vasodilator
properties.
However, the profound changes in vascular loading may
have confounded the observed effects on diastolic and contrac-
tile function. The significant decrease in tau may have been
produced by the reduction in afterload. Tau is known to be
afterload-dependent, particularly in heart failure (5–7). Also,
marked decreases in loading may have falsely elevated the
improvement in Ees (Fig. 1). In a canine model, Kass et al. (8)
have shown that the slope of the end-systolic pressure–volume
relation is nonlinear, being concave away from the volume axis,
and as contractility is depressed this relation becomes more
linear (9). The investigators concluded that Ees is accurate to
assess contractility only in limited load ranges and may not be
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accurate when there are significant changes in loading. Accord-
ingly, we minimized the potentially confounding effects of
vascular loading on diastolic and contractile variables by
administering intracoronary OPC-18790 to eight patients with
congestive heart failure, and we determined the direct myo-
cardial effects of this drug using pressure–volume relations. We
hypothesized that with intracoronary doses (31.25 to 62.5
mg/min) comparable to those used intravenously (5 to 10 mg/kg
body weight per min), OPC-18790 would have a reduced positive
inotropic effect and that an improvement in isovolumetric relax-
ation would persist despite the absence of changes in afterload,
due to phosphodiesterase inhibition of OPC-18790.
Methods
Patients. Eight patients (mean age 57 6 8 years) with
congestive heart failure referred for elective cardiac catheter-
ization at the University of Virginia were enrolled in this study.
Four patients were in New York Heart Association functional
class II and four patients were in class III. Congestive heart
failure was due to idiopathic dilated cardiomyopathy in five
patients, ischemic cardiomyopathy in two and hypertensive
heart disease in one. All patients had a baseline pulmonary
capillary wedge pressure $15 mm Hg and an ejection fraction
#35%. Patients were excluded from the study if they had atrial
fibrillation, received any inotropic agent other than digoxin
within 4 weeks of the study or had symptomatic ventricular
tachycardia, left ventricular apical thrombus or primary valvu-
lar heart disease. Six patients were taking captopril (mean daily
dose 38.5 6 19.5 mg); all patients were taking oral furosemide
(mean daily dose 48.6 6 38.0 mg); and three patients were
taking digoxin (mean daily dose 0.21 6 0.07 mg). All vasodi-
lators were withheld for at least 24 h before cardiac catheter-
ization. In a ninth patient, the study was terminated early due
to patient restlessness. This patient’s incomplete data were
excluded from the analysis. Written informed consent was
obtained from all patients, and the protocol was approved for
use by the human investigational committee of the Hospital of
the University of Virginia.
Instrumentation and protocol. Patients underwent routine
right and left heart catheterization, left ventriculography and
coronary arteriography. Additional femoral artery access was
obtained for the 5F left coronary catheter, which was used to
infuse intracoronary OPC-18790 during the protocol. A non-
ionic contrast agent was used to minimize the potential nega-
tive inotropic effects of contrast. After the diagnostic study,
conductance and micromanometer catheters were advanced to
the left ventricular apex, as described previously (10). Baseline
hemodynamic variables were recorded at least 30 min after the
diagnostic catheterization and included heart rate, mean right
atrial pressure, pulmonary artery pressure, pulmonary artery
wedge pressure, aortic pressure, left ventricular end-diastolic
and systolic pressures, thermodilution cardiac output and
stroke volume. Transient balloon catheter (SP-9168, Cordis)
obstruction of the inferior vena cava was performed to gener-
ate pressure–volume relations from beats at decreasing pre-
loads. Steady state conditions were rapidly restored after
balloon deflation. Data were digitized at 200 Hz by use of
custom acquisition and display software. After baseline data
were measured, OPC-18790 was infused into the left main
coronary artery at a dose of 31.25 mg/min for 20 min and then
at 62.5 mg/min for another 20 min. Hemodynamic measure-
ments, including pressure–volume relations obtained at steady
state and during transient inferior vena caval occlusion, were
taken at the end of the 31.25-mg/min infusion and then again at
the end of the 62.5-mg/min infusion. Peripheral venous samples
were drawn at each time point and for up to 2 h after the
beginning of the protocol (11). The intracoronary doses were
calculated to produce coronary sinus concentrations similar to
the venous concentrations produced by intravenous infusion by
Feldman et al. (1), based on a coronary flow rate of 125 ml/min
(12), so that the intracoronary dose of 31.25 mg/min corre-
sponded to 5.0 mg/kg per min given intravenously and 62.5
mg/min corresponded to 10.0 mg/kg per min. There were no
adverse events in any of the eight patients studied. Neither
arrhythmias nor an increase in baseline atrial or ventricular
ectopy was noted during OPC-18790 infusion.
Conductance catheter technique. The conductance cathe-
ter technique and its principles have been fully described
previously (10). A 7F or 8F conductance catheter (Webstar
Abbreviations and Acronyms
CO 5 cardiac output
dP/dt 5 rate of rise in left ventricular pressure
dV/dt 5 maximal rate of change of left vetricular volume
Ea 5 arterial elastance
EDV 5 end-diastolic volume
Ees 5 end-systolic elastance
MSW 5 preload recruitable stroke work
MV˙O2 5 myocardial oxygen consumption
PWRmax 5 maximal power index
SVR 5 systemic vascular resistance
Figure 1. Diagram illustrating the curvilinear nature of the end-
systolic pressure–volume relation (8). This figure demonstrates that by
reducing loading conditions and not changing contractility, the as-
sumed linear end-systolic pressure–volume relation (B) becomes
steeper, implying greater contractility (C), due to the true curvilinear
end-systolic pressure–volume relation (A).
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Labs), with a 2F micromanometer (Millar Instruments) placed
within its lumen, was used. Under fluoroscopic guidance,
catheters were placed along the long axis of the left ventricle
and connected to a digital stimulator microprocessor (Sigma
V, Leycom [dual-field system]). An excitation current was
applied to electrodes at the apex and the aortic root, and
resistance differences were measured between intervening
electrode pairs. The inverse of each resistance is proportional
to segmental volume, and the sum of these segments yielded
total volume. It has been previously demonstrated that the
conductance catheter accurately measures changes in left
ventricular volume during the cardiac cycle in normal and
abnormal ventricles (13). The conductance catheter signal gain
was calibrated with the thermodilution-derived stroke volume.
This correction was made at each drug dose. The calibration
offset (parallel conductance) was corrected by matching the
conductance catheter signal at end-diastole with the end-
diastolic volume (EDV) measured by ventriculography. Using
the Kennedy-Dodge regression (14), single-plane ventriculo-
graphic volumes were obtained which have been shown to
correlate well with biplane ventriculographic volumes, even in
patients with dyskinetic or depressed ventricles (15). Left
ventriculography was performed at baseline and at the end of
the 62.5-mg/min infusion.
Data analysis. Using custom software, digitized hemody-
namic data were analyzed off-line. To eliminate any 60-Hz
noise, pressure–volume data were smoothed with a three-point
moving average. Steady state hemodynamic measurements
were determined from signal-averaged cardiac cycles, combin-
ing 5 to 10 sequential beats. Pressure–volume relations were
obtained from a set of cardiac cycles during preload reduction,
starting at the beat just before the onset of the left ventricular
pressure decline and ending with the nadir of the pressure
decline, or before a reflex increase of .5% in heart rate for
three consecutive beats. Extrasystolic beats and at least two
post-extrasystolic beats were excluded from the analysis.
Hemodynamic variables. 1) Preload was defined as EDV
and was measured by left ventriculography. 2) Arterial loading
was determined by systemic vascular resistance (SVR 5
[mAoP 2 mRAP]/CO), where mAoP 5 mean aortic pressure;
mRAP 5 mean right atrial pressure; and CO 5 cardiac output,
and by arterial elastance (Ea 5 ESP/SV), where ESP 5
end-systolic pressure; and SV 5 stroke volume. SVR quantifies
mean resistance, whereas Ea incorporates both mean and
pulsatile components of the arterial load (16). 3) Systolic pump
function variables included CO, stroke volume and stroke
work. Stroke work was defined as the area enclosed by the
pressure–volume relation. 4) Contractility was assessed by four
methods: the ratio of maximal rate of rise in left ventricular
pressure (dP/dt) to EDV (17), the slope of the end-systolic
pressure–volume relation (Ees) (18), the slope of the stroke
work to EDV relation (MSW) (19) and the ratio of the maximal
power index (PWRmax) to EDV
2 (20). 5) dP/dt was derived
digitally by the use of a five-point weighted slope. 6) End-
systolic pressure–volume points were fit by perpendicular regres-
sion to derive Ees. 7) Stroke work and 8) EDV were measured
for the same set of beats, and the relation was fit by linear
regression, to yield the slope (MSW). 9) PWRmax was the
product of peak instantaneous pressure and flow (left ventric-
ular pressure and dV/dt). PWRmax was divided by EDV
2 to
minimize load dependence, as previously described and vali-
dated (20).
Diastolic function. Diastolic variables included the dia-
stolic pressure–volume relation and the time constant for
isovolumic relaxation (tau). Tau was calculated by regressing
left ventricular pressure versus dP/dt during the isovolumic
relaxation phase (21). Other variables measured included
minimal left ventricular pressure, the driving pressure for left
ventricular filling (expressed as the difference between the V
wave of the pulmonary artery wedge pressure and minimal left
ventricular pressure), left ventricular end-diastolic pressure
(the lower right-hand corner of the pressure–volume loop),
peak positive dV/dt and peak negative dP/dt.
Ventriculoarterial coupling and myocardial efficiency.
Ventriculoarterial coupling was determined by the Ees/Ea
ratio. This ratio reflects the matching of left ventricular
contractility to arterial loading. In normal subjects, this ratio is
typically $1.5, and it declines to ,0.5 in patients with conges-
tive heart failure (22). Such reduced ratios reflect a depressed
left ventricular contractile state (low Ees) coupled with a high
vascular resistance (high Ea). An increase in this ratio would be
predicted to increase ventricular work and efficiency (stroke
work/MV˙O2) (23). Myocardial oxygen consumption (MV˙O2)
was estimated by the pressure–work index (PWI) of Rooke and
Feigl (24), calculated by PWI 5 4.08 p 1024 p (sAoP p HR) 1
3.25 p 1024 p (0.8 sAoP 2 0.2 dAoP) p (HR p SV/BW) 1 1.43,
where sAoP and dAoP 5 systolic and diastolic aortic pressure;
HR 5 heart rate; and BW 5 body weight (kg). This method
has been shown to correlate reasonably well with directly
measured MV˙O2 (25). Both stroke work and MV˙O2 were
expressed in joules.
Statistical analysis. Data are expressed as the mean
value 6 SEM. Drug-induced changes were tested for by
repeated measures analysis of variance, and multiple compar-
isons were performed by using a t test with the Bonferroni
correction.
Results
Effect of intracoronary OPC-18790 on heart rate and
vascular load (Table 1). Heart rate was not significantly
altered by either dose of OPC-18790. There was a small but
significant effect on right heart load as determined by a fall in
right atrial pressure, and a more pronounced effect on mean
pulmonary artery wedge pressure. These effects were greater at
62.5 mg/min than at 31.25 mg/min. There were no significant
effects on arterial load as determined by SVR index and Ea, or
preload as determined by left ventricular EDV.
Effect of intracoronary OPC-18790 on systolic function,
ventriculoarterial coupling and efficiency (Table 2). There
were no significant effects on stroke volume, CO or stroke
work. Among the more load-insensitive measures of contrac-
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tile function, there was a significant increase in the ratio of
maximal dP/dt to EDV by 74% and an increase in Ees by 85%
(Fig. 2). MSW and PWRmax, both of which are dependent on
changes in stroke volume, end-systolic pressure and stroke
work, were not affected by either dose. Ventriculoarterial
coupling, defined by the ratio of Ees/Ea, significantly improved
by 80%, as there was a significant increase in Ees without any
change in Ea. Efficiency remained constant, as there was no
significant change in either stroke work or estimated MV˙O2.
Effect of intracoronary OPC-18790 on diastolic function
(Table 3). There was a significant reduction in tau, reflecting
enhanced active relaxation, without any significant difference
between the two doses. Although preload as determined by
EDV was not affected, there was a small fall in right atrial
pressure and a larger fall in pulmonary artery wedge pressure
(Table 1). There was also a significant decrease in minimal left
ventricular end-diastolic pressure. Consistent with this fall in
pressure, without any change in volume, inspection of the
pressure–volume relations revealed a downward shift, consis-
tent with pericardial release in five of the eight patients studied
(Fig. 3).
Plasma concentrations of OPC-18790. Despite the intra-
coronary route of delivery, systemic levels were detectable.
Plasma concentrations of OPC-18790 peaked at 54 6 7 ng/ml
at the end of the second 20-min infusion and fell thereafter to
12 6 4 at 2 h. These levels are much lower than the peripheral
levels from the equivalent dose of 10.0 mg/kg per min admin-
istered intravenously by Feldman et al. (1), who reported levels
of 782 6 50 ng/ml at this dose after 45 min of infusion.
Discussion
The present study demonstrates that in the absence of a
reduction in preload (EDV) and afterload (Ea), intracoronary
OPC-18790 is a modest inotrope. The rise in Ees in the current
study, using intracoronary administration, was much less than
that found with comparable intravenous doses used previously
(1), consistent with curvilinearity of the end-systolic pressure–
volume relation (Fig. 1). Improvement of isovolumic relaxation
was also demonstrated in the absence of a reduction of
afterload. In addition, the small fall in right atrial pressure
results in a marked reduction in pulmonary artery wedge
pressure, without any change in EDV, due to pericardial
release. These effects are accompanied by improved ventricu-
loarterial coupling, constant efficiency and no increase in heart
rate. These results imply that OPC-18790 is a favorable agent
for the intravenous treatment of congestive heart failure.
Inotropic effects. The current study confirms that OPC-
18790 is a weak inotrope. When intracoronary OPC-18790 was
administered at 31.25 and 62.5 mg/min, there was a significant
increase in Ees of 22% to 85% and an increase in the ratio of
Table 1. Effects of Intracoronary OPC-18790 on Heart Rate and
Vascular Load
Baseline 31.25 mg/min 62.5 mg/min p Value
HR (beats/min) 88 6 4 87 6 4 86 6 4 NS
mRAP (mm Hg) 9 6 1 8 6 1 7 6 1* , 0.01
mPAP (mm Hg) 32 6 3 27 6 2 26 6 3 0.05
sPAP (mm Hg) 43 6 4 37 6 3 34 6 4 , 0.005
dPAP (mm Hg) 23 6 3 20 6 2 19 6 3 0.07
mPAW (mm Hg) 21 6 3 18 6 2 16 6 2* , 0.05
EDV (ml) 177 6 12 173 6 12 NS
mAoP (mm Hg) 101 6 6 101 6 6 100 6 6 NS
sAoP (mm Hg) 142 6 9 142 6 9 145 6 10 NS
dAoP (mm Hg) 78 6 4 80 6 4 80 6 4 NS
SVR (dyneszszcm25) 1,802 6 161 1,870 6 205 1,991 6 235 NS
PVR (dyneszszcm25) 203 6 22 191 6 32 223 6 45 NS
Ea (mm Hg/ml) 3.1 6 0.3 3.1 6 0.3 3.3 6 0.4 NS
*p , 0.05 versus 31.25-mg/min dose. Data are presented as mean value 6
SEM. dAoP 5 diastolic aortic pressure; dPAP 5 diastolic pulmonary artery
pressure; Ea 5 arterial elastance; EDV 5 end-diastolic volume; HR 5 heart
rate; mAoP 5 mean aortic pressure; mPAP 5 mean pulmonary artery pressure;
mPAW 5 mean pulmonary artery wedge pressure; mRAP 5 mean right atrial
pressure; PVR 5 pulmonary vascular resistance; sAoP 5 systolic aortic pressure;
sPAP 5 systolic pulmonary artery pressure; SVR 5 systemic vascular resistance.
Table 2. Effects of Intracoronary OPC-18790 on Systolic Function, Ventriculoarterial Coupling and
Myocardial Efficiency
Baseline 31.25 mg/min 62.5 mg/min p Value*
SV by td (ml) 47 6 4 49 6 5 47 6 5 NS
CI by td (liters/min per m2) 2.4 6 0.1 2.4 6 0.2 2.3 6 0.2 NS
SW (mm Hg/ml) 5,168 6 700 5,381 6 842 5,627 6 725 NS
dP/dtmax/EDV (mm Hgzs
21zml21) 3.5 6 0.5 4.2 6 0.6 6.1 6 0.8 , 0.005
Ees (mm Hg/ml) 0.74 6 0.11 0.90 6 0.16 1.37 6 0.33 , 0.05
MSW (mm Hg) 42 6 8 55 6 8 47 6 6 NS
PWRmax/EDV
2 (W/ml2z1,000) 2.95 6 0.76 3.49 6 0.91 3.47 6 1.16 NS
Ees/Ea ratio 0.25 6 0.05 0.30 6 0.06 0.45 6 0.12 , 0.05
MV˙O2 2.12 6 0.12 2.14 6 0.13 2.17 6 0.12 NS
Efficiency† (%) 31.8 6 2.6 32.6 6 2.8 34.0 6 2.7 NS
*By repeated measures analysis of variance. †Myocardial efficiency (stroke work/myocardial oxygen consumption).
Data are presented as mean value 6 SEM. CI 5 cardiac index; dP/dtmax/EDV 5 preload-adjusted peak rate of rise in
left ventricular pressure; Ees 5 end-systolic elastance; Ees/Ea 5 ratio of end-systolic elastance to arterial elastance;
MSW 5 preload recruitable stroke work; MV˙O2 5 predicted myocardial oxygen consumption (ml O2/beat per 100 g);
PWRmax/EDV
2 5maximal power index; SV 5 stroke volume; SW 5 stroke work; td 5 thermodilution method.
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maximal dP/dt to EDV of 20% to 74%. Other indexes of
contractility, such as MSW and PWRmax, were not significantly
affected by either dose. These changes in contractility are much
less than those found with the equivalent intravenous doses of
5 to 10 mg/kg per min of OPC-18790, which increased Ees by
124% to 172% in the study of Feldman et al. (1). The effects of
intravenous OPC-18790 on Ees may have been overestimated
(1). It has been shown in animal studies (8,9) that the slope of
the end-systolic pressure–volume relation is concave away
from the volume axis. With reduced loading conditions and no
change in contractility, the end-systolic pressure–volume rela-
tion would have moved to a steeper part of the curve (Fig. 1),
giving the false appearance of an inotropic effect. Because this
curvilinear relation is further enhanced by an increase in
contractility, the 124% to 172% increase in Ees with intrave-
nous OPC-18790 administration is an overestimation, as con-
firmed in the present study.
Despite being a weak inotrope, OPC-18790 develops less
Figure 2. Examples of pressure–volume loops
during inferior vena caval occlusion from patients
receiving intracoronary OPC-18790 (top) and in-
travenous OPC-18790 (bottom) at baseline (A
and C) and at either 62.5 mg/min by intracoronary
infusion (B) or the equivalent intravenous dose of
10 mg/kg per min (D). Note that with intracoro-
nary infusion the end-diastolic and end-systolic
volumes do not change (first loop of the ramp),
whereas with intravenous infusion there are
marked decreases in both end-diastolic and end-
systolic volumes, which may lead to an overesti-
mation of the improvement in Ees.
Table 3. Effects of Intracoronary OPC-18790 on Diastolic Function
Baseline 31.25 mg/min 62.5 mg/min p Value
Tau (ms) 94 6 9 79 6 9* 78 6 8 , 0.05
2dP/dtmin (mm Hgzs
21) 21,063 6 93 21,183 6 102 21,197 6 119 0.06
LVmin (mm Hg) 15 6 1 13 6 1 11 6 2 , 0.05
PAW(V) 2 LVmin (mm Hg) 7 6 2 5 6 2 5 6 2 NS
LVEDP (mm Hg) 23 6 1 20 6 2 20 6 2 , 0.05
dV/dt (mlzs21) 440 6 42 396 6 29 485 6 38 0.06
*p , 0.05 compared with baseline value. Data are presented as mean value 6 SEM. 2dP/dtmin 5 peak negative rate
of rise in left ventricular pressure; dV/dt 5 peak early diastolic first derivative of volume; LVmin 5 minimal left
ventricular pressure; LVEDP 5 left ventricular end-diastolic pressure; PAW(V) 5 V wave of pulmonary artery wedge
pressure.
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tachyphylaxis and decrease in adenylate cyclase activity than
with dobutamine (26), which results in sustained elevations in
the cardiac index and dP/dt over 1 week in animals treated with
dobutamine. We hypothesize that these effects are caused by
some of the unique cellular features of OPC-18790 compared
with more traditional agents. The inotropic effects of OPC-
18790 are due primarily to inhibition of phosphodiesterase-III
(2), although other electrophysiologic effects that result in a
prolonged action potential and reduced potassium repolariza-
tion currents may also contribute to the inotropic effects (4).
Although phosphodiesterase inhibitors generally increase
heart rate, the inotropic effects of OPC-18790 are not accom-
panied by changes in heart rate. The increase in heart rate
found with traditional beta-agonists and phosphodiesterase
inhibitors partly explains their less favorable effects on effi-
ciency compared with OPC-18790 (27). Illustrating the impor-
tance of the chronotropic effects on MV˙O2, Yamakawa et al.
(28) demonstrated that the negative chronotropic effects of
beta-blockade offset the mechanoenergetic deterioration re-
sulting from negative inotropic effects. This absence of heart
rate effects has also been shown to minimize changes in high
energy phosphate metabolites when OPC-18790 is adminis-
tered to a globally ischemic guinea pig heart model, and these
results were in contrast to those in studies with amrinone or
dobutamine (29).
Diastolic effects. In isolated muscle, OPC-18790 shortens
relaxation (2). In human heart failure, previous investigators
have demonstrated that intravenous OPC-18790 shortens tau.
However, tau, which reflects the active portion of ventricular
relaxation, is known to be afterload-dependent (5–7), so a
concomitant reduction in afterload may also reduce tau.
Ishikaza et al. (5) have shown, in a canine pacing tachycardia-
induced heart failure model, that there is a steeper relation
between tau and end-systolic force after development of heart
failure. Eichorn et al. (7) have made the same observations in
patients with heart failure. These studies imply that in heart
failure, the afterload sensitivity of tau is even greater. Other
investigators have suggested that this does not mean enhanced
load sensitivity in heart failure, but rather that the relation
between end-systolic force and tau is J shaped, with the steep
portion of the curve seen when end-systolic forces are mark-
edly elevated in heart failure (6). Because no significant
changes in afterload were seen in this study, the observed
decrease in tau reflects improved diastolic function. In hu-
mans, Hoit et al. (3) have shown that OPC-18790 improves
early diastolic filling. They demonstrated that the posterior
wall thinning rates were increased and also that early diastolic
transmitral flow was unchanged despite a reduction in pulmo-
nary artery wedge pressure, suggesting that the early diastolic
transmitral gradient was maintained by a beneficial effect on
isovolumic left ventricular relaxation. They also demonstrated
that the pulmonary artery wedge pressure was lower, although
EDV was unchanged, which was attributed to a change in the
passive diastolic chamber compliance. However, we also ob-
served a similar decrease in pulmonary artery wedge pressure
and no change in EDV. We interpreted this to be due to
pericardial release in five of eight patients (Fig. 3). This
Figure 3. The diastolic portions of the pressure–volume loops in all
eight patients are shown. In Patients 1 to 5, there is evidence of
pericardial release with OPC-18790, with a reduction in left ventricular
(LV) pressure without a change in volume. Open squares 5 baseline;
solid circles 5 62.5-mg/min dose (the 31.25-mg/min dose is excluded to
aid in clarity).
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demonstrates how the use of pressure–volume loops allows a
more mechanistic interpretation of these interrelating factors,
which are not appreciable with other methods.
Tau, as calculated from the semilogarithmic slope of pres-
sure versus time, as described by Weiss et al. (30), is dependent
on transmural pressures (31) and could be affected by release
of the pericardium observed in this study. However, the
calculation of tau in this study involves plotting the first
derivative of pressure against pressure (21) and is independent
of pericardial pressures. Despite the shortening of active
relaxation, as measured by tau, and the associated fall in
minimal left ventricular pressure, there was only a borderline
increase in dV/dt (p 5 0.06). The driving gradient for left
ventricular filling (the difference between the V wave of the
pulmonary artery wedge pressure and minimal left ventricular
pressure) was not significantly changed, which explains the
absence of a significant increase in dV/dt. Inspection of the
diastolic portion of the pressure–volume curves demonstrates
that in five of the eight patients there was a parallel downward
translation of the relation, consistent with pericardial release.
Dauterman et al. (32) have shown that the pericardium can
contribute significantly to filling pressures, so that when the
diastolic pressure at rest is .6 mm Hg, almost 38% of the
pressure is due to external factors. The phenomenon of
pericardial release is seen early after decreases in preload
(32,33), equivalent to the small decrease in right atrial pres-
sure, with no change in left ventricular EDV, seen in this study.
This resulted in a fall in both pulmonary artery wedge pressure
and left ventricular diastolic pressures, with the result that the
driving pressure across the mitral valve (V wave of pulmonary
artery wedge pressure 2 minimal left ventricular pressure) did
not increase as expected. Because the driving gradient across
the mitral valve is a major determinant of dV/dt (34), the
absence of change in mitral driving gradient shown in Table 3
would attenuate the predicted increase in dV/dt.
Conclusions. Intracoronary administration of OPC-18790
demonstrates that the direct myocardial effects of this drug
include a modest increase in inotropy, improvement in dia-
stolic function and no change in heart rate. These effects result
in lowered left heart filling pressures, (partly due to pericardial
release), improved ventriculoarterial coupling, constant MV˙O2
and myocardial efficiency, without provoking arrhythmias.
These results indicate that this agent may be a useful alterna-
tive to more traditional agents for intravenous treatment of
congestive heart failure.
References
1. Feldman MD, Pak PH, Wu CC, et al. Acute cardiovascular effects of
OPC-18790 in patients with congestive heart failure: time- and dose-
dependence analysis based on pressure–volume relations. Circulation 1996;
93:474–83.
2. Endoh M, Kawabata Y, Katano Y, Norota I. Effects of a novel cardiotonic
agent (6)-6-[3-(3,4-dimethoxybenzylamino)-2-hydroxypropoxyl]-2(1H)-
quinolone (OPC-18790) on contractile force, cyclic AMP level, and aequorin
light transients in dog ventricular myocardium. J Cardiovasc Pharmacol
1994;23:723–30.
3. Hoit DB, Burwig S, Eppert D, Bhat G, Walsh RA. Effects of a novel
inotropic agent (OPC-18790) on systolic and diastolic function in patients
with severe heart failure. Am Heart J 1994;128:1156–63.
4. Iijima T, Taira N. Membrane current changes responsible for the positive
inotropic effect of OPC-8212, a new positive inotropic agent, in single
ventricular cells of the guinea pig heart. J Pharmacol Exp Ther 1987;240:
657–62.
5. Ishikaza S, Asanoi H, Wada O, Kameyama T, Inoue H. Loading sequence
plays an important role in enhanced load sensitivity of left ventricular
relaxation in conscious dogs with tachycardia-induced cardiomyopathy.
Circulation 1995;92:3560–7.
6. Sys SU, Brutsaert DL. Diagnostic significance of impaired LV systolic
relaxation in heart failure. Circulation 1995;92:3377–80.
7. Eichorn EJ, Willard JE, Alvarez L, et al. Are contraction and relaxation
coupled in patients with and without congestive heart failure? Circulation
1992;85:2132–9.
8. Kass DA, Beyar R, Lankford E, Heard M, Maughan WL, Sagawa K.
Influence of contractile state on curvilinearity of in situ end-systolic pres-
sure–volume relations. Circulation 1989;79:167–78.
9. Suga H, Yamada O, Goto Y, Igarashi Y. Peak isovolumic pressure–volume
relation of puppy left ventricle. Am J Physiol 1986;250:H167–72.
10. Kass DA, Midei M, Graves W, Maughan WL. Use of a conductance catheter
and transient inferior vena caval occlusion for rapid determination of
pressure–volume relationships in man. Cathet Cardiovasc Diagn 1988;15:
192–202.
11. Kitani M, Miyamoto G, Odomi M. Stereoselective high-performance liquid
chromatographic assay for the determination of OPC-18790 enantiomers in
human plasma and urine. J Chromatogr B Biomed Appl 1993;620:97–104.
12. Ganz W, Tamura K, Marcus HS, Donoso R, Yoshida S, Swan HJC.
Measurement of coronary sinus blood flow by continuous thermodilution in
man. Circulation 1971;44:181–95.
13. Odake M, Takeuchi M, Takaoka H, Hata K, Hayashi Y, Yokoyama M.
Determination of left ventricular volume using a conductance catheter in the
diseased human heart. Eur Heart J 1992;13 Suppl E:22–7.
14. Kennedy JW, Trenholme SE, Kasser IS. Left ventricular volume and mass
from single-plane cineangiocardiogram. Am Heart J 1970;80:343–52.
15. Brogan WC III, Glamann B, Lange RA, Hillis LD. Comparison of single and
biplane ventriculography for determination of left ventricular volume and
ejection fraction. Am J Cardiol 1992;69:1079–82.
16. Kelly RP, Ting CT, Yang TM, Maughan WL, Chang MS, Kass DA. Effective
arterial elastance as index of arterial vascular load in humans. Circulation
1992;86:513–21.
17. Kass DA, Maughan WL, Guo ZM, Kono A, Sunagawa K, Sagawa K.
Comparative influence of load versus inotropic states on indexes of ventric-
ular contractility: experimental and theoretical analysis based on pressure–
volume relationships. Circulation 1987;76:1422–36.
18. Suga H, Sagawa K. Instantaneous pressure–volume relationships and their
ratio in the excised, supported canine left ventricle. Circ Res 1974;35:117–28.
19. Glower DD, Spratt JA, Snow ND, et al. Linearity of the Frank-Starling
relationship in the intact heart: the concept of preload recruitable stroke
work. Circulation 1985;71:994–1009.
20. Sharir T, Feldman M, Haber H, Marmor A, Becker LC, Kass DA.
Ventricular systolic assessment in patients with dilated cardiomyopathy by
preload-adjusted maximal power: validation and noninvasive application.
Circulation 1994;89:2045–53.
21. Raff GL, Glantz SA. Volume loading slows left ventricular isovolumic
relaxation rate. Circ Res 1981;48:813–24.
22. Asnaoi H, Sasayama S, Kameyama T. Ventriculoarterial coupling in normal
and failing heart in humans. Circ Res 1989;65:483–93.
23. Sunagawa K, Maughan WL, Sagawa K. Optimal arterial resistance for
maximal stroke work studied in isolated canine ventricle. Circ Res 1985;56:
586–95.
24. Rooke GA, Feigl EO. Work as a correlate of canine left ventricular oxygen
consumption, and the problem of oxygen wasting. Circ Res 1982;50:273–86.
25. Schipke JD, Burkhoff D, Kass DA, Alexander J Jr, Schaefer J, Sagawa K.
Hemodynamic dependence of myocardial oxygen consumption indexes.
Am J Physiol 1990;258:H1281–91.
26. Fujika H, Mori T, Tominaga M. Effects of OPC-18790 on hemodynamic and
the b-adrenergic receptor pathway in conscious dogs: a comparison with
dobutamine. CHF 1996;July/August:12–20.
27. Kanda H, Yokota M, Ishihara H, Nagata K, Kato R, Sobue T. A novel
inotropic vasodilator, OPC-18790, reduces myocardial oxygen consumption
1350 MACGOWAN ET AL. JACC Vol. 31, No. 6
OPC-18790 IN HEART FAILURE May 1998:1344–51
and improves mechanical efficiency with congestive heart failure. Am Heart J
1996;132:362–81.
28. Yamakawa H, Takeuchi M, Takaoka H, Hata K, Mori M, Yokoyama M.
Negative chronotropic effect of b-blockade therapy reduces myocardial
oxygen expenditure for nonmechanical work. Circulation 1996;94:340–5.
29. Itoh S, Mori T, Tominaga M, Ishikawa M, Koga K, Yabuuchi Y. Differential
effects of OPC-18790, amrinone, and dobutamine on cardiac function and
energy metabolism in the guinea-pig isolated ischaemic heart. Br J Pharma-
col 1995;114:1090–6.
30. Weiss JL, Frederiksen JW, Weisfeldt ML. Hemodynamic determinants of
the time-course of fall in canine left ventricular pressure. J Clin Invest
1976;58:751–60.
31. Frais MA, Bergman DW, Kingma I, Smiseth OA, Smith ER, Tyberg JV. The
dependence of the time constant of left ventricular isovolumic relaxation (t)
on pericardial pressure. Circulation 1990;81:1071–80.
32. Dauterman K, Pak PH, Maughan WL, et al. Contribution of external forces
to left ventricular diastolic pressure: implications for the clinical use of the
Starling law. Ann Intern Med 1995;122:737–42.
33. Brodie BR, Grossman W, Mann T, McLaurin LP. Effects of sodium
nitroprusside on left ventricular diastolic pressure–volume relations. J Clin
Invest 1977;59:59–68.
34. Ohno M, Cheng CP, Little WC. Mechanism of altered patterns of left
ventricular filling during development of congestive heart failure. Circulation
1994;89:2241–50.
1351JACC Vol. 31, No. 6 MACGOWAN ET AL.
May 1998:1344–51 OPC-18790 IN HEART FAILURE
